Chris Viehbacher, Managing Partner of Gurnet Point Capital, leads a $2 billion healthcare fund that invests across all. See sector focus and contact routes.
Chris Viehbacher, Managing Partner of Gurnet Point Capital, leads a $2 billion healthcare fund that invests across all stages from venture innovations to growth buyouts, with check sizes ranging from $500K to over $1B[2][9]. The firm focuses on biotechnology, pharmaceuticals, medical devices, and diagnostics, targeting de-risked companies developing innovative therapies for unmet medical needs[2][7]. Notable portfolio companies include Biohaven Pharmaceuticals, Corvidia Therapeutics, and Boston Pharmaceuticals, which received a $600M initial commitment to develop phase III-ready assets[2][3][5]. Viehbacher’s distinctive thesis emphasizes being proactive “business builders” rather than passive syndicate investors, prioritizing assets with validated mechanisms and clear commercial potential[9][15].
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Cambridge when building a target list.
Investors like Chris Viehbacher · Full investor directory · Investor access · Company funding database